Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis ...

The botulinum toxin market is projected to grow at a CAGR of approximately 10% from 2025 to 2030. This growth is driven by ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real world impacts, among other things, can help, explains Bennett Smith.

Amalgamated Financial Corp. ('Amalgamated” or the 'Company”) (Nasdaq: AMAL) today announced that its Board of Directors has declared a regular dividend to common stockholders of $0.14 per share, ...

Evolus is demonstrating strong market share gains, successful new product launches, and reaffirmed 2025 revenue guidance despite recent share price volatility. Read the stock analysis here.